Inclusion Criteria:  To be eligible, patients must meet all of the following criteria:  Ages 18 to 65, inclusive Must have a transtibial amputation Must be using a prosthesis within the vicinity of 3 months or have had osteo-integration of a prosthetic in place for 1 month Friction and pressure related skin problems or discomfort or an active superficial epidermal ulcer without penetration through the entire dermis (for multiple ulcers, only one will be treated). In the opinion of the investigator, must be medically able to undergo the administration of study material determined by laboratory tests obtained within 7 days before baseline for which the investigator identified no clinically significant abnormality. Able to provide written informed consent Females of childbearing potential must: have a negative pregnancy test at screening agree to not become pregnant or breastfeed for the period of the study through 1 month after completion of the study be willing to use a reliable form of contraception during the study. Have healthy skin as determined by the investigator or study Nurse Practitioner. Willing and able to comply with the scheduled visits, biopsy/injection procedures, wound care instructions treatment plan, and other study procedures for the duration of the study.  Exclusion Criteria:  An individual who meets any of the following criteria will be excluded from participation in this study:  A skin erosion deeper than the skin dermis. Ulcers exceeding 4cm in diameter or 2cm in radius Non circular ulcers that cannot tolerate a 1cm margin at all sides Having received any investigational drug within 30 days prior to study entry An allergy history to any study materials including local anesthetic, dimethyl sulfoxide, human albumin, or bovine constituents, hetastarch, or EMLA (lidocaine 2.5% and prilocaine 2.5%). Pregnant, lactating, or trying to become pregnant A history of keloid formation Having a significant medical history that the investigator feels is not safe for study participation (for example, some forms of autoimmune conditions, metastatic cancer, infectious diseases such as HIV, HTLV I/II, Hepatitis B, Hepatitis C). Biopsies taken from individuals with infections that are not allowed to enter the cell therapy core will make it such that these individuals cannot participate. Autoimmune diseases affecting the skin such as lupus. Presence of necrotic ischemic tissue on any stump ulcers, and/or capillary refill on stump skin of greater than 3 seconds Active infection of the residual limb. Active smoker during the study We will also exclude those who are on chronic immunosuppressive therapies such as oral steroids, but also those on chronic topical steroids in the area of investigation. Amputees with neuromas of the terminal limb within the last 3 months. Known bleeding disorder. Positive immunogenicity test: history of serious allergy, such as anaphylaxis Have a history of congenital or idiopathic methemoglobinemia, glucose-6-phosphate deficiencies, or use of medications associated with drug-induced methemoglobinemia. (specifically: Sulfonamides, Acetaminophen, Acetanilid, Aniline dyes, Benzocaine, Chloroquine, Dapsone, Naphthalene, Nitrates and Nitrites, Nitrofurantoin, Nitroglycerin, Nitroprusside, Pamaquine, Paraaminosalicylic acid, Phenacetin, Phenobarbital, Phenytoin, Primaquine, or Quinine.) Quadriplegics